| Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial M Weller, N Butowski, DD Tran, LD Recht, M Lim, H Hirte, L Ashby, ... The Lancet Oncology 18 (10), 1373-1385, 2017 | 943 | 2017 |
| Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma KM Field, J Simes, AK Nowak, L Cher, H Wheeler, EJ Hovey, CSB Brown, ... Neuro-oncology 17 (11), 1504-1513, 2015 | 149 | 2015 |
| Interleukin-6: an angiogenic target in solid tumours K Middleton, J Jones, Z Lwin, JIG Coward Critical reviews in oncology/hematology 89 (1), 129-139, 2014 | 147 | 2014 |
| Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study M van Den Bent, HK Gan, AB Lassman, P Kumthekar, R Merrell, ... Cancer chemotherapy and pharmacology 80, 1209-1217, 2017 | 133 | 2017 |
| Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I … AB Lassman, MJ Van Den Bent, HK Gan, DA Reardon, P Kumthekar, ... Neuro-oncology 21 (1), 106-114, 2019 | 97 | 2019 |
| Factors impacting survival following second surgery in patients with glioblastoma in the temozolomide treatment era, incorporating neutrophil/lymphocyte ratio and time to first … MG McNamara, Z Lwin, H Jiang, AJ Templeton, G Zadeh, M Bernstein, ... Journal of neuro-oncology 117, 147-152, 2014 | 93 | 2014 |
| Neutrophil–lymphocyte ratio dynamics during concurrent chemo-radiotherapy for glioblastoma is an independent predictor for overall survival M Mason, C Maurice, MG McNamara, MT Tieu, Z Lwin, BA Millar, ... Journal of neuro-oncology 132, 463-471, 2017 | 85 | 2017 |
| Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma HK Gan, DA Reardon, AB Lassman, R Merrell, M Van Den Bent, ... Neuro-oncology 20 (6), 838-847, 2018 | 74 | 2018 |
| “It doesn’t exist…”: negotiating palliative care from a culturally and linguistically diverse patient and caregiver perspective E Kirby, Z Lwin, K Kenny, A Broom, H Birman, P Good BMC palliative care 17, 1-10, 2018 | 67 | 2018 |
| Outcomes after second surgery for recurrent glioblastoma: a retrospective case–control study A Wann, PA Tully, EH Barnes, Z Lwin, R Jeffree, KJ Drummond, H Gan, ... Journal of neuro-oncology 137, 409-415, 2018 | 64 | 2018 |
| LBA41 LEAP-005: Phase II study of lenvatinib (len) plus pembrolizumab (pembro) in patients (pts) with previously treated advanced solid tumours Z Lwin, C Gomez-Roca, E Saada-Bouzid, E Yanez, FL Muñoz, SA Im, ... Annals of Oncology 31, S1170, 2020 | 61 | 2020 |
| A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU study HW Sim, KL McDonald, Z Lwin, EH Barnes, M Rosenthal, MC Foote, ... Neuro-Oncology 23 (10), 1736-1749, 2021 | 53 | 2021 |
| Lenvatinib plus pembrolizumab for patients with previously treated biliary tract cancers in the multicohort phase II LEAP-005 study. L Villanueva, Z Lwin, HC Chung, C Gomez-Roca, F Longo, E Yanez, ... Journal of Clinical Oncology 39 (3_suppl), 321-321, 2021 | 47 | 2021 |
| Immune checkpoint inhibitors: navigating a new paradigm of treatment toxicities K Roberts, V Culleton, Z Lwin, K O'Byrne, BGM Hughes Asia‐Pacific Journal of Clinical Oncology 13 (4), 277-288, 2017 | 44 | 2017 |
| A phase I study of temozolomide and everolimus (RAD001) in patients with newly diagnosed and progressive glioblastoma either receiving or not receiving enzyme-inducing … WP Mason, M MacNeil, P Kavan, J Easaw, D Macdonald, B Thiessen, ... Investigational new drugs 30, 2344-2351, 2012 | 38 | 2012 |
| Negotiating palliative care in the context of culturally and linguistically diverse patients A Broom, P Good, E Kirby, Z Lwin Internal medicine journal 43 (9), 1043-1046, 2013 | 37 | 2013 |
| Conditional probability of survival and post-progression survival in patients with glioblastoma in the temozolomide treatment era MG McNamara, Z Lwin, H Jiang, C Chung, BA Millar, A Sahgal, ... Journal of neuro-oncology 117, 153-160, 2014 | 36 | 2014 |
| The continuing role of chemotherapy for advanced non-small cell lung cancer in the targeted therapy era Z Lwin, JW Riess, D Gandara Journal of thoracic disease 5 (Suppl 5), S556, 2013 | 36 | 2013 |
| Glioblastoma management in the temozolomide era: have we improved outcome? Z Lwin, D MacFadden, A Al-Zahrani, E Atenafu, BA Miller, A Sahgal, ... Journal of neuro-oncology 115, 303-310, 2013 | 34 | 2013 |
| Efficacy of a novel antibody-drug conjugate (ADC), ABT-414, as monotherapy in epidermal growth factor receptor (EGFR) amplified, recurrent glioblastoma (GBM). MJ Van Den Bent, HK Gan, AB Lassman, P Kumthekar, R Merrell, ... Journal of clinical oncology 34 (15_suppl), 2542-2542, 2016 | 33* | 2016 |
Alex BroomProfessor of Sociology, The University of SydneyVerified email at sydney.edu.au
